Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
Date:3/12/2008

s in salaries and related personnel costs (including an increase of $1.5 million in stock-based compensation charges) from the planned addition of general and administrative staff in 2007 as compared to 2006, and costs related to operating as a public company.

Financial Outlook for 2008

Cadence currently anticipates that total operating expenses for full year 2008 will be between $54 million and $59 million including an estimated $4 to $6 million in non-cash stock-based compensation expenses. Cadence expects that cash, cash equivalents and investments held for sale at December 31, 2008, will be between $41 million and $46 million.

Acetavance(TM) Clinical Program

-- In January 2008, Cadence announced topline results from two Phase III

clinical trials of Acetavance, Study 301 and Study 302. While Study

301, which evaluated Acetavance in the treatment of pain following

abdominal gynecologic surgery, successfully achieved several secondary

endpoints, including pain relief, global patient satisfaction and time

to administration of rescue medication, the study did not meet its

primary endpoint of demonstrating a statistically significant reduction

in patients' pain intensity levels over 48 hours compared to placebo.

Study 302, a Phase III clinical trial of Acetavance in fever,

successfully met its primary endpoint, demonstrating a statistically

significant reduction of fever over six hours compared to placebo. In

both studies, Acetavance demonstrated a favorable safety profile, which

was similar to placebo.

-- In January 2008, Cadence also initiated communications with the FDA to

obtain additional guidance regarding its clinical development program

for Acetavance. Cadence expects to receive such guidance from the FDA

in the second quarter of 2008. Based upon the outcome of these

communicatio
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
2. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
3. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
4. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
5. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
6. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
7. Drinking Water Association Discusses Pharmaceuticals in Water
8. Genesis Pharmaceuticals Changes Auditors
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
11. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... News) -- Thanksgiving meals can pose a challenge for ... expert says. Many traditional Thanksgiving dishes -- such ... are gluten-free, but "when it comes to pies, stuffing, ... Dr. Anca Safta, director of the Gluten and Allergic ... in North Carolina, said in a center news release. ...
(Date:11/27/2014)... Indian Trail, NC (PRWEB) November 27, 2014 ... for over 12 years in the Charlotte area ... and fraud examination services to businesses of varying ... with local business owners to meet all of ... received QuickBooks certification through the QuickBooks ProAdvisor Program. ...
(Date:11/27/2014)... November 27, 2014 Two international trainers ... procedure will help one person with significant needs ... Saj Jivraj and Dr. Mamaly Reshad of the Anacapa ... have launched a website devoted to helping dentist learn ... the website would be devoted to helping a patient ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “LAB.C” ... Report, which features the latest and coolest technology products available ... NewsWatch, conducted the product review and shared with ... cable for iOS and Android devices. , Consumers love portability ... LAB.C. Their Cable Case for the iPhone5 and 5S ...
(Date:11/27/2014)... This is a professional and in ... an overview analysis, the report introduces Insulin basic ... industry overview, policy analysis, and news analysis, etc. ... information on policy, plans for Insulin Market product ... more. , This report also provides ...
Breaking Medicine News(10 mins):Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:Top Mobile Friendly Accessories were Featured on NewsWatch Television on October 30, 2014 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3
... possibility of risk of cerebral palsy , , WEDNESDAY, Sept. ... of steroids in-utero had no additional growth or neurodevelopmental ... studies found. , However, one of the studies did ... the incidence of cerebral palsy. , "In our ...
... the expanded use of FluMist (influenza virus vaccine live, intranasal) ... now approved for active immunization for the prevention of disease ... to 49 years of age. 1 Only one manufacturer ... influenza vaccine for children under four years of age. , ...
... That Tout Nutrition and Health, WESTLAKE ... of nutrition,in every bite! Dole Packaged Foods, ... Nutritious(TM) Signature Blends-unique combinations of,all-natural frozen fruit ... selections enriched with antioxidants and,immunity health components, ...
... Force, Retaining Cataract Sales ... Force and Lowering Operating Costs, MONROVIA, Calif., ... reported progress in its deployment of a,direct U.S. sales force ... in the retention of key sales,representatives for its cataract products. ...
... A molecular recycling plant permits nerve cells in ... changeable enough to record new experiences, yet permanent ... discovery of this molecular recycling plant, detailed in a ... Neuron, provides new insights into how the basic units ...
... shrink the size of tumors, but some might ... population of cancer stem cells believed to drive ... Atlanta, Georgia at the American Association for Cancer ... in Cancer Therapeutic Development. , Our experiments suggest ...
Cached Medicine News:Health News:Steroids Seem Safe for Babies at Risk of Early Birth 2Health News:Steroids Seem Safe for Babies at Risk of Early Birth 3Health News:Dole Invites Consumers to Show Their Wild Side! 2Health News:STAAR Surgical Reports Operational Progress 2Health News:STAAR Surgical Reports Operational Progress 3Health News:STAAR Surgical Reports Operational Progress 4Health News:New understanding of basic units of memory 2Health News:To evade chemotherapy, some cancer cells mimic stem cells 2
(Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the ... been recognized as a winner of Red Herring,s ... Global Top 100 North America award in 2013, marking ... technology landscape. Red Herring,s Top 100 Global ... promising new companies and entrepreneurs. Red Herring editors were ...
(Date:11/26/2014)... 25, 2014   Heska Corporation (NASDAQ: ... a provider of advanced veterinary diagnostic and other specialty ... Executive Chair, will attend The Benchmark Company, LLC,s Micro Cap ... will be held at The Palmer House Hilton, 17 E. ... a.m. to 2:30 p.m. Please email hska@haydenir.com or ...
(Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... Safety and Efficacy Data Presented at 1st IASLC-ESMO European Lung ... ... 23 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company ... 2,clinical trial of picoplatin confirming previously announced interim,results showing a survival ...
... 23 Archus Orthopedics, Inc.,announced today that it ... TFAS-C(TM) system, the newest addition to the company,s ... which degenerative changes in,the facet joints result in ... legs. Traditionally, patients with moderate to,severe spinal stenosis ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 2Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 3Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 4First Human Implant of New Archus Orthopedics Facet Replacement System 2
Validated by decades of research and clinical experience, HFA is the accepted standard of care in glaucoma diagnosis and management. With HFA you can feel confident you're providing the best possible...
... Rapidlab 1200's speed and accuracy allow ... in a timely manner - something ... especially patients. In fact, the Rapidlab ... in just one minute. Its maintenance-free, ...
... challenges. One complete solution. , Increased requirements ... Staff turnover. These are just some of ... challenges that can impact the amount of ... , , You can't afford ...
Dornier Holmium Laser for Urological Procedures...
Medicine Products: